Rigel announces GAVRETO trial data publication

Rigel Pharmaceuticals has announced the publication of final ARROW clinical trial data for GAVRETO (pralsetinib) in patients with RET-altered non-small cell lung cancer (NSCLC). The data, featured in the Journal of Clinical Oncology, provides comprehensive insights into the efficacy and safety of GAVRETO. This publication represents a significant step in disseminating important clinical findings within the oncology community. It supports the ongoing understanding and potential application of GAVRETO in treating specific lung cancer patient populations.